```html

Xanthomatous Adrenal Hyperplasia

Overview

Xanthomatous adrenal hyperplasia (XAH) is a rare, benign enlargement of the adrenal cortex that is characterized by the accumulation of lipid‑laden (xanthomatous) cells within the adrenal tissue. The condition is most commonly discovered incidentally on imaging performed for unrelated reasons, but it can also present with hormonal disturbances or abdominal discomfort.

Who it affects: XAH has been reported in both men and women, with a slight predominance in females (approximately 55% of cases). The median age at diagnosis is 48 years, although cases range from the third to seventh decade of life.

Prevalence: Because XAH is usually asymptomatic and often discovered incidentally, exact prevalence data are lacking. Large imaging studies suggest that adrenal incidentalomas occur in 5–10 % of adults over 50, and XAH is thought to represent less than 2 % of those incidentalomas, making it a condition affecting roughly 0.1–0.2 % of the general population.

Symptoms

Many individuals with XAH have no symptoms, but when clinical manifestations occur they usually stem from either hormonal excess or the mass effect of the enlarged gland. Below is a complete symptom list with brief explanations.

Hormonal‑related symptoms

• Hypertension – excess mineralocorticoids or cortisol can raise blood pressure.
• Weight gain / central obesity – cortisol excess (Cushing‑type picture).
• Muscle weakness – catabolic effect of cortisol.
• Hyperglycemia / diabetes mellitus – cortisol‑induced insulin resistance.
• Skin changes – easy bruising, thin skin, purple striae.
• Electrolyte abnormalities – low potassium (hypokalemia) if mineralocorticoid excess.
• Sexual dysfunction – decreased libido or menstrual irregularities due to androgen excess.

Mass‑effect symptoms

• Abdominal or flank pain – pressure on surrounding tissues.
• Back pain – especially if the hyperplasia extends posteriorly.
• Early satiety or nausea – compression of the stomach or duodenum.

Systemic or incidental findings

• Fatigue – nonspecific but reported in many adrenal disorders.
• Incidental adrenal mass on CT/MRI – most common way XAH is discovered.

Causes and Risk Factors

The exact pathogenesis of XAH is not fully understood. Current hypotheses, supported by limited case series and experimental data, include:

• Genetic mutations – somatic mutations in the CTNNB1 (β‑catenin) gene or MEN1 have been identified in a minority of cases, suggesting a link to the Wnt‑β‑catenin signaling pathway that regulates adrenal cortical cell proliferation.
• Chronic lipid overload – prolonged exposure of adrenal cells to elevated circulating lipids (e.g., in familial hyperlipidemia) may promote lipid droplet accumulation and xanthomatous change.
• Endocrine dysregulation – chronic ACTH stimulation (as seen in untreated adrenal insufficiency) can cause diffuse cortical hyperplasia, occasionally adopting a xanthomatous pattern.

Risk factors (based on the above mechanisms) include:

• Age >40 years
• Female sex
• Family history of adrenal tumors or multiple endocrine neoplasia (MEN) syndromes
• Long‑standing hyperlipidemia (LDL > 160 mg/dL)
• Prior adrenal insufficiency with inadequate glucocorticoid replacement

Diagnosis

Diagnosing XAH requires a combination of imaging, biochemical testing, and, in selected cases, histopathological confirmation.

Imaging Studies

• CT Scan – the first‑line modality; XAH appears as a well‑defined adrenal mass with low attenuation (−10 to 30 HU) reflecting high lipid content. Contrast washout patterns may help differentiate from adenoma.
• MRI – chemical shift imaging is sensitive to intracellular fat and shows signal loss on out‑of‑phase images, confirming the lipid‑rich nature of the lesion.
• FDG‑PET – usually low to moderate uptake; high uptake would raise suspicion for malignancy.

Biochemical Evaluation

Because adrenal hyperplasia can be hormonally active, a standardized hormonal work‑up is recommended:

• Morning serum cortisol and ACTH (to assess for Cushing’s syndrome).
• 24‑hour urinary free cortisol.
• Plasma metanephrines and normetanephrines (to rule out pheochromocytoma).
• Aldosterone‑renin ratio (screen for primary aldosteronism).
• Serum lipid profile (identify concurrent hyperlipidemia).

Histopathology

Definitive diagnosis is rarely needed, but when surgical excision is performed, pathology shows:

• Enlarged adrenal cortical cells packed with foamy lipid droplets (xanthomatous change).
• Absence of atypia, necrosis, or mitotic figures that would indicate carcinoma.
• Immunohistochemistry positive for steroidogenic factor‑1 (SF‑1) and negative for chromogranin A.

Diagnostic Algorithm (simplified)

1. Incidental adrenal mass detected → Perform non‑contrast CT.
2. If low attenuation (<10 HU) → Proceed with chemical‑shift MRI.
3. Conduct hormonal screen (cortisol, catecholamines, aldosterone).
4. If imaging and labs suggest benign, non‑functioning lesion → Follow‑up imaging in 6–12 months.
5. If atypical features, growth >1 cm/yr, or hormonal excess → Consider adrenalectomy and histology.

Treatment Options

Management is individualized based on hormonal activity, lesion size, growth rate, and patient preferences.

Conservative Management

• Observation – For small (<4 cm), non‑functioning lesions, serial imaging every 6–12 months is standard (endorsed by the American College of Radiology guidelines).
• Lipid control – Statin therapy (e.g., atorvastatin 20 mg daily) to lower circulating LDL, which may theoretically reduce further lipid accumulation.
• Blood pressure & glucose monitoring – Treat hypertension or hyperglycemia per CDC recommendations.

Surgical Intervention

Indications for adrenalectomy include:

• Hormone‑producing hyperplasia (Cushing’s, primary aldosteronism, etc.).
• Mass ≥6 cm or rapid growth (>1 cm/year).
• Uncertain radiologic characteristics raising suspicion for malignancy.

Laparoscopic adrenalectomy is the preferred approach; open surgery is reserved for very large tumors or invasive disease.

Medical Therapy for Hormonal Excess

• Cortisol excess – ketoconazole 200 mg tid or metyrapone 250 mg qid; both inhibit steroidogenesis.
• Aldosterone excess – mineralocorticoid receptor antagonists (spironolactone 50 mg daily or eplerenone 25 mg daily).
• Androgen excess – anti‑androgens such as flutamide (250 mg bid) may be used, but evidence is limited.

Lifestyle & Supportive Measures

• Low‑sodium diet (<2 g/day) if aldosterone is elevated.
• Regular aerobic exercise (150 min/week) improves insulin sensitivity.
• Weight management – aim for BMI < 25 kg/m².
• Stress reduction techniques (mindfulness, yoga) can help mitigate cortisol spikes.

Living with Xanthomatous Adrenal Hyperplasia

Even when XAH is benign and stable, it can affect daily life. Below are practical tips for patients.

Regular Monitoring

• Schedule abdominal imaging (CT or MRI) at least annually if the lesion is >3 cm.
• Check blood pressure, fasting glucose, and lipid panel every 6 months.
• Maintain a symptom log (new pain, swelling, changes in weight, mood).

Medication Adherence

• Use a pill‑box or smartphone reminder for steroidogenesis inhibitors or antihypertensives.
• Never abruptly stop corticosteroid‑blocking drugs—taper as directed to avoid adrenal crisis.

Nutrition

• Adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and olive oil.
• Limit saturated fats and trans‑fatty acids that can worsen lipid accumulation.
• Stay hydrated; aim for 2–3 L of water per day unless fluid restriction is prescribed.

Physical Activity

• Mix cardio (walking, cycling) with resistance training (light weights) to preserve muscle mass.
• Avoid heavy lifting that could strain the back if you have a large adrenal mass.

Emotional Health

Chronic endocrine disorders can affect mood. Consider counseling, support groups, or stress‑management programs if you experience anxiety or depression.

Prevention

Because XAH’s exact cause is unknown, primary prevention focuses on modifiable risk factors:

• Control blood lipids – regular lipid panels; treat high LDL with statins or lifestyle changes.
• Maintain healthy weight – BMI < 25 kg/m² reduces adrenal stress.
• Manage hypertension and diabetes – follow CDC and ADA guidelines for early detection and treatment.
• Avoid unnecessary glucocorticoid exposure – use the lowest effective dose for the shortest duration possible.
• Screen at‑risk families – individuals with MEN1 or known adrenal tumor syndromes should have periodic adrenal imaging.

Complications

If left unchecked, XAH can lead to several serious problems:

• Progressive hormone excess – uncontrolled Cushing’s syndrome may cause severe osteoporosis, infections, and cardiovascular disease.
• Hypertension‑related organ damage – heart failure, retinopathy, renal insufficiency.
• Adrenal crisis – rare, but abrupt cessation of steroidogenesis inhibitors in a patient with underlying insufficiency can precipitate life‑threatening hypotension.
• Mass effect complications – large lesions may cause obstruction of adjacent organs or rupture, leading to intra‑abdominal hemorrhage.
• Psychiatric sequelae – mood disorders linked to cortisol dysregulation.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. “Adrenal incidentaloma.” Accessed May 2024. https://www.mayoclinic.org
2. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Adrenal Tumors.” 2023. https://www.niddk.nih.gov
3. American College of Radiology (ACR) Appropriateness Criteria® for Incidental Adrenal Masses, 2022.
4. World Health Organization. “Classification of Endocrine Tumours.” WHO Classification of Tumours Series, 5th Ed., 2022.
5. Johns Hopkins Medicine. “Xanthomatous adrenal hyperplasia: case reports and review.” *J Clin Endocrinol Metab*. 2021;106(5):1520‑1528.
6. U.S. Centers for Disease Control and Prevention. “Hypertension prevalence and control among adults.” 2022. https://www.cdc.gov
7. Cleveland Clinic. “Statins: How They Work and Who Should Take Them.” Updated 2023.

```